NCT01907867View on ClinicalTrials.gov

Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Safety and Tolerability
Interventions
DRUG

Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days

Trial Locations (1)

85006

Pulmonary Associates, PA, Phoenix

Sponsors
All Listed Sponsors
lead

MerLion Pharmaceuticals GmbH

INDUSTRY

NCT01907867 - Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin | Biotech Hunter | Biotech Hunter